Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 4 hours ago
ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’
about 4 hours ago
The German biotech shared updated data from a phase 1 study of...
Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
about 24 hours ago
Nine years after wowing the audience at the American Society of Clinical...
Entry Japan with Clarity, Execute with Confidence
1 day ago
For biopharmaceutical companies, Japan is one of the world’s most important markets...
AstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval
1 day ago
AstraZeneca has shared data it believes can rescue anselamimab from a phase...
Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed
1 day ago
Agios Pharmaceuticals’ next-gen pyruvate kinase (PK) activator has failed a phase 2...
Boston, China and the future of biotech
1 day ago
Senior Writer Darren Incorvaia talks with industry leaders and experts from Flagship...
Chutes & Ladders—Allogene swaps in CMO as new chief exec
1 day ago
After more than eight years at the helm of off-the-shelf CAR-T company...
ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study
1 day ago
Bristol Myers Squibb may have gone big in its pursuit of cereblon...
ASCO: Lilly debuts ‘strong’ bladder cancer data for potential Padcev challenger
1 day ago
Eli Lilly took to the stage at the American Society of Clinical...
Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist field
1 day ago
Gilead has abandoned work on the lead rheumatoid arthritis drug from its...
Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
1 day ago
Pfizer is paying Innovent $650 million upfront to partner on cancer drug...
FDA extends Beren’s rare disease review after info request, further stretching saga
2 days ago
The FDA has delayed its approval decision on Beren Therapeutics’ rare disease...